Atlanta, GA – Scibility Media – 11/14/2014.
This article discusses two companies: Revance Therapeutics Inc(NADAQ:RVNC) and RCS Capital Corp(NYSE:RCAP)
Revance Therapeutics Inc(NADAQ:RVNC) reported its third quarter financial results on Nov. 12th, 2014. The company reported a loss from operations of $13.8 million and a cash and cash equivalent total of $187.5 million. The California-based biopharmaceutical company develops, manufactures, and commercializes novel botulinium toxin products.
The company traded for as little as $14.02 during yesterday’s trading, a new 52 week low for Revance Therapeutics. Yesterday’s loss was affected by an increased interest in the stock, which had a trading volume of 2.30 million for the day. This figure dwarfs the company’s three month average volume of 0.18 million, suggesting that traders have taken notice of Revance Therapeutics.
RCS Capital Corp(NYSE:RCAP)participated in the Bank of America Merrill Lynch Banking and Financial Services Conference on Nov. 13th, 2014. The company also reported its third quarter operating results on that same date, announcing a net income of $35.5 million, or $0.40 per fully diluted share. The company is currently being sued by American Realty Capital for terminating an agreement to purchase a business.
Like Revance Therapeutics, RCS Capital also traded for a new 52 week low of $8.94 during yesterday’s trading, a figure which is $30.04 lower than its high of $39.98 for the same period. The company also saw its trading volume spike to a figure of 7.28 million yesterday. Simply put, RCS Capital is currently trending downward.
EquiPress.com is a non-advertisement based network (currently in limited release) designed for investors to discover and communicate with publicly traded companies in real-time.
Sign-up for free now to experience the full benefits of EquiPress pre-launch.
Discover and communicate with companies you would otherwise never have seen based on your interests, company news, personalized news feeds, and one-on-one communications with no middle-men nor advertisements. Read our no advertisements pledge.
Can’t find your company on EquiPress? Send us an email to email@example.com and we will contact them for you.
Interested in a one month free trial? Get access to our private investor network, real-time news distribution, automatic disclaimers, corporate analytics, verified public profile, and industry-wide marketing of your corporate news.
Disclosure: EquiPress is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. EquiPress does not hold any equity or financial interest in any publicly traded company. EquiPress provides a uniform subscription based service to all publicly traded companies on a monthly basis at a rate of $495 to provide investor awareness. EquiPress receives only cash compensation from clients. Despite the relationship, EquiPress maintains a neutral stance (nonbiased) on any investment related opinions and exists solely for the purpose of allowing investors to communicate with the publicly traded companies in an effort to establish for themselves investment considerations. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor. Please visit www.equipress.com for complete risks and disclosures.